Lalwani Nikhil's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Nov 27, 2024
- Accession no.
- 0001822629-24-000014
- Filed
- Nov 27, 2024
- Trade date
- Nov 26, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.94M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lalwani NikhilCIK 0001822629 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | Common Stock | MOption exerciseAcquired | +30,000 | $29.00 | +$870,000 | 403,859 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −30,000 | $57.95F1 | −$1,738,500 | 373,859 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −3,481 | $58.30F2 | −$202,942.3 | 370,378 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | Common Stock | MOption exerciseDisposed | −30,000 | $29.00 | −$870,000 | 138,027 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $57.76 to $58.55. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F2
The shares were sold in multiple trades at prices ranging from $58.18 to $58.61. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.